Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after...
share announcement

10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after the Discovery

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 8908

Special Issue Editor

Dr. M. Esther Gallardo

E-Mail Website
Guest Editor
Head of Translational Research with iPS Cells Group, Research Institute Hospital 12 de Octubre, i+12, Madrid, Spain
Interests: induced pluripotent stem cells; McArdle disease; mitochondrial disorders; modeling disorders; CRISPR/Cas9; drug repurposing studies; tissue engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is our great pleasure to announce the 10th anniversary of the journal Biomedicines. Over the last decade, more than 3,023 articles, on all aspects of research on human health and disease, have been published in Biomedicines. Remarkably, in the last few years, the impact factor of the journal has increased considerably. We are very grateful for the dedicated support of the authors, reviewers, editors, and readers of this journal, as without this support, this important achievement would not have been possible.

To celebrate this anniversary, we are launching a Special Issue entitled “10th Anniversary of Biomedicines—Induced pluripotent stem cells: 15 years after the discovery”. Since the creation of induced pluripotent stem cells (iPSCs), by the Nobel Prize laureate Dr. Shinya Yamanaka, many laboratories worldwide are working to generate and apply these cells to the investigation of the ethiopathogeny behind diseases and the search for new therapies against them. The aim of this Special Issue is to collect high-quality papers, fully dedicated to iPSCs and their applications, from top experts in this field. In particular, we encourage researchers to present comprehensive review papers and original articles that highlight the most recent advances in this topic.

Dr. M. Esther Gallardo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • induced pluripotent stem cells
  • organoids
  • tissue engineering
  • biomaterials
  • reprogramming
  • iPSC-based cell modelling
  • cell therapy
  • microfluidics
  • drug discovery

Related Special Issue

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2207 KiB  
Article
Creation of an iPSC-Based Skeletal Muscle Model of McArdle Disease Harbouring the Mutation c.2392T>C (p.Trp798Arg) in the PYGM Gene
by Victoria Cerrada, Inés García-Consuegra, Joaquín Arenas and M. Esther Gallardo
Biomedicines 2023, 11(9), 2434; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines11092434 - 31 Aug 2023
Viewed by 1090
Abstract
McArdle disease is a rare autosomal recessive condition caused by mutations in the PYGM gene. This gene encodes the skeletal muscle isoform of glycogen phosphorylase or myophosphorylase. Patients with McArdle disease have an inability to obtain energy from their muscle glycogen stores, which [...] Read more.
McArdle disease is a rare autosomal recessive condition caused by mutations in the PYGM gene. This gene encodes the skeletal muscle isoform of glycogen phosphorylase or myophosphorylase. Patients with McArdle disease have an inability to obtain energy from their muscle glycogen stores, which manifests as a marked exercise intolerance. Nowadays, there is no cure for this disorder and recommendations are intended to prevent and mitigate symptoms. There is great heterogeneity among the pathogenic variants found in the PYGM gene, and there is no obvious correlation between genotypes and phenotypes. Here, we present the generation of the first human iPSC-based skeletal muscle model harbouring the second most frequent mutation in PYGM in the Spanish population: NM_005609.4: c.2392T>C (p.Trp798Arg). To this end, iPSCs derived from a McArdle patient and a healthy control were both successfully differentiated into skeletal muscle cells using a small molecule-based protocol. The created McArdle skeletal muscle model was validated by confirming distinctive biochemical aspects of the disease such as the absence of myophosphorylase, the most typical biochemical feature of these patients. This model will be very valuable for use in future high-throughput pharmacological screenings. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after the Discovery)
►▼ Show Figures

Figure 1

17 pages, 3074 KiB  
Article
Rapid Generation of Pulmonary Organoids from Induced Pluripotent Stem Cells by Co-Culturing Endodermal and Mesodermal Progenitors for Pulmonary Disease Modelling
by Adam Mitchell, Chaowen Yu, Xiangjun Zhao, Laurence Pearmain, Rajesh Shah, Karen Piper Hanley, Timothy Felton and Tao Wang
Biomedicines 2023, 11(5), 1476; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines11051476 - 18 May 2023
Cited by 1 | Viewed by 1854
Abstract
Differentiation of induced pluripotent stem cells to a range of target cell types is ubiquitous in monolayer culture. To further improve the phenotype of the cells produced, 3D organoid culture is becoming increasingly prevalent. Mature organoids typically require the involvement of cells from [...] Read more.
Differentiation of induced pluripotent stem cells to a range of target cell types is ubiquitous in monolayer culture. To further improve the phenotype of the cells produced, 3D organoid culture is becoming increasingly prevalent. Mature organoids typically require the involvement of cells from multiple germ layers. The aim of this study was to produce pulmonary organoids from defined endodermal and mesodermal progenitors. Endodermal and mesodermal progenitors were differentiated from iPSCs and then combined in 3D Matrigel hydrogels and differentiated for a further 14 days to produce pulmonary organoids. The organoids expressed a range of pulmonary cell markers such as SPA, SPB, SPC, AQP5 and T1α. Furthermore, the organoids expressed ACE2 capable of binding SARS-CoV-2 spike proteins, demonstrating the physiological relevance of the organoids produced. This study presented a rapid production of pulmonary organoids using a multi-germ-layer approach that could be used for studying respiratory-related human conditions. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after the Discovery)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

31 pages, 2643 KiB  
Review
Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments
by Yoshikazu Kishino and Keiichi Fukuda
Biomedicines 2023, 11(3), 915; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines11030915 - 15 Mar 2023
Cited by 5 | Viewed by 2734
Abstract
Patients with chronic heart failure (HF) have a poor prognosis due to irreversible impairment of left ventricular function, with 5-year survival rates <60%. Despite advances in conventional medicines for HF, prognosis remains poor, and there is a need to improve treatment further. Cell-based [...] Read more.
Patients with chronic heart failure (HF) have a poor prognosis due to irreversible impairment of left ventricular function, with 5-year survival rates <60%. Despite advances in conventional medicines for HF, prognosis remains poor, and there is a need to improve treatment further. Cell-based therapies to restore the myocardium offer a pragmatic approach that provides hope for the treatment of HF. Although first-generation cell-based therapies using multipotent cells (bone marrow-derived mononuclear cells, mesenchymal stem cells, adipose-derived regenerative cells, and c-kit-positive cardiac cells) demonstrated safety in preclinical models of HF, poor engraftment rates, and a limited ability to form mature cardiomyocytes (CMs) and to couple electrically with existing CMs, meant that improvements in cardiac function in double-blind clinical trials were limited and largely attributable to paracrine effects. The next generation of stem cell therapies uses CMs derived from human embryonic stem cells or, increasingly, from human-induced pluripotent stem cells (hiPSCs). These cell therapies have shown the ability to engraft more successfully and improve electromechanical function of the heart in preclinical studies, including in non-human primates. Advances in cell culture and delivery techniques promise to further improve the engraftment and integration of hiPSC-derived CMs (hiPSC-CMs), while the use of metabolic selection to eliminate undifferentiated cells will help minimize the risk of teratomas. Clinical trials of allogeneic hiPSC-CMs in HF are now ongoing, providing hope for vast numbers of patients with few other options available. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after the Discovery)
►▼ Show Figures

Graphical abstract

20 pages, 656 KiB  
Review
iPSC-Derived Cardiomyocytes in Inherited Cardiac Arrhythmias: Pathomechanistic Discovery and Drug Development
by Eline Simons, Bart Loeys and Maaike Alaerts
Biomedicines 2023, 11(2), 334; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines11020334 - 25 Jan 2023
Cited by 2 | Viewed by 1970
Abstract
With the discovery of induced pluripotent stem cell (iPSCs) a wide range of cell types, including iPSC-derived cardiomyocytes (iPSC-CM), can now be generated from an unlimited source of somatic cells. These iPSC-CM are used for different purposes such as disease modelling, drug discovery, [...] Read more.
With the discovery of induced pluripotent stem cell (iPSCs) a wide range of cell types, including iPSC-derived cardiomyocytes (iPSC-CM), can now be generated from an unlimited source of somatic cells. These iPSC-CM are used for different purposes such as disease modelling, drug discovery, cardiotoxicity testing and personalised medicine. The 2D iPSC-CM models have shown promising results, but they are known to be more immature compared to in vivo adult cardiomyocytes. Novel approaches to create 3D models with the possible addition of other (cardiac) cell types are being developed. This will not only improve the maturity of the cells, but also leads to more physiologically relevant models that more closely resemble the human heart. In this review, we focus on the progress in the modelling of inherited cardiac arrhythmias in both 2D and 3D and on the use of these models in therapy development and drug testing. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after the Discovery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop